The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Oklahoma Health Campus Renamed After $150M Hamm Gift

The University of Oklahoma will rename its Oklahoma City health campus after a $150 million gift from energy executive Harold Hamm, the largest single donation in the university's history, according to a Sept. 22 news release shared with Becker's Hospital Review.

The campus is home to OU Health, the state's only academic health system. Naming an entire health campus after a single donor reflects a broader pattern in academic medicine, where major philanthropy underwrites clinical, research, and educational infrastructure that operating margins and state funding alone often cannot cover. Academic health systems face thin margins, aging facilities, and rising costs, making transformational gifts a critical funding source.

For OU Health, the money offers capital to expand capacity and research in a state that relies heavily on it for advanced and specialty care. The gift also ties one of Oklahoma's most prominent business figures directly to the future of its medical education and delivery, a relationship other academic systems increasingly cultivate to fund growth.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.